bluebird bio’s plans to file for approval of lovotibeglogene autotemcel (lovo-cel) in severe sickle cell disease (SCD) in the first quarter of 2023 will no doubt ignite debate over its cost-effectiveness. A study presented at the American Society of Hematology annual meeting looked beyond traditional criteria for cost effectiveness, concluding that despite the gene therapy’s presumably high price tag, it could be an equitable therapeutic strategy in a wider pool of eligible patients.
Sickle Cell Gene Therapy Cost Effectiveness Draws Scrutiny At ASH
According to a study presented at the American Society of Hematology, based on existing gene therapy prices, equitable use of sickle cell disease gene therapy requires expanding into patients who are younger and have less severe disease.
More from Drug Pricing
More from Scrip
• By
Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.
• By
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies